Bridging the Poles: What the Transcranial Magnetic Stimulation Evidence Tells Us About Bipolar Depression

Bipolar depression remains one of the most therapeutically challenging phases of mood disorders. Despite substantial progress in pharmacotherapy, many patients experience inadequate response or side effects, and the risk of mood polarity switching complicates antidepressant use. In contrast, transcranial magnetic stimulation (TMS) has emerged as a safe and effective neuromodulatory treatment for unipolar major depression, now widely implemented across clinical settings (1,2). However, its role in bipolar depression has long been underexplored, hindered by small trials, heterogeneous methodologies, and enduring safety concerns regarding treatment-emergent mania.

In this context, the recent systematic review and meta-analysis by Ventura et al. (3) in Biological Psychiatry: Global Open Science provides the most comprehensive synthesis to date of the efficacy, effectiveness, and safety of TMS in bipolar depression. By compiling data across stimulation modalities and clinical contexts, their work addresses a crucial gap in the literature and invites a broader reflection on how neuromodulation fits within the therapeutic framework of bipolar depression, moving from categorical exclusion toward evidence-based inclusion.

The authors’ analysis demonstrates a moderate and statistically significant antidepressant effect of active TMS compared with sham, with standardized mean differences in the range of 0.4 to 0.6, comparable with the effect sizes that have typically been reported for pharmacological antidepressants in bipolar depression. However, direct comparisons remain limited, as few head-to-head trials have evaluated TMS against established pharmacotherapies, which itself represents a gap for future research (1,4). Importantly, no increased risk of manic or hypomanic switching was detected, an observation that is consistent with consensus data indicating only isolated cases of treatment-emergent mania, typically under left-sided high-frequency stimulation (4). Collectively, these findings challenge longstanding cautionary views and support the broader, evidence-based clinical use of TMS in bipolar depression.

The authors also emphasize the heterogeneity of stimulation parameters, including target sites (most frequently the left dorsolateral prefrontal cortex), frequency, and treatment duration. However, across modalities, results consistently favored active stimulation. By synthesizing findings from both controlled and open-label designs, Ventura et al. (3) move beyond early proof-of-concept trials to demonstrate the broader feasibility and tolerability of TMS in bipolar depression. These findings echo recent real-world data including both unipolar and bipolar treatment-resistant depression populations, which have shown the effectiveness and tolerability of accelerated TMS protocols in clinical settings (5). Collectively, their findings help clarify that bipolar depression, long treated as an exception in neuromodulation research, responds to TMS with an efficacy comparable with that observed in unipolar depression.

While Ventura et al. (3) convincingly establish that TMS exerts therapeutic benefit in bipolar depression, their meta-analysis also highlights important methodological constraints. Protocols varied in stimulation intensity, number of sessions, and maintenance schedules, while diagnostic criteria often combined bipolar I and II disorders without stratified analyses. Such variability may obscure potential differences in treatment response across subtypes, illness phases, or concomitant medication regimens.

More broadly, the existing evidence base is limited by small sample sizes, modest blinding integrity, and inconsistent sham conditions, all of which may compromise reproducibility. The inclusion of both repetitive TMS and deep TMS protocols adds further neurophysiological diversity, because these modalities do not necessarily engage identical cortical and subcortical circuits. Recognizing these limitations, Ventura et al. (3) call for greater standardization of stimulation parameters and more systematic monitoring of safety and clinical outcomes.

From a conceptual standpoint, the current meta-analysis underscores the need to move from categorical to dimensional models of mood disorders. The response profiles shared by unipolar and bipolar depression suggest overlapping neurobiological substrates, possibly within frontolimbic or salience networks (6). TMS, by targeting nodes common to both conditions, may thus operate transdiagnostically. Integrating this perspective could guide the next generation of neuromodulation studies, emphasizing network dysfunctions rather than diagnostic boundaries.

Clinically, the findings of Ventura et al. (3) provide reassurance that TMS is a viable and safe therapeutic option for patients with bipolar depression, particularly for those with treatment resistance or intolerance to pharmacotherapy. The absence of an increased risk of manic switch should encourage clinicians to reconsider the place of TMS in the treatment algorithm. Historically, patients with bipolar depression have often been excluded or underserved in interventional research and clinical practice, owing to concerns about polarity switching. The current synthesis helps redress this imbalance: It supports a more confident and evidence-based use of TMS, allowing bipolar depression to be approached with the same therapeutic ambition as unipolar depression.

Nonetheless, evidence remains insufficient to define optimal stimulation parameters for bipolar populations. Comparative trials of high-frequency left versus low-frequency right stimulation, or intermittent theta-burst protocols, are needed to refine clinical guidelines. As Ventura et al. (3) highlight, functional outcomes remain underrepresented in the current evidence base. From a translational perspective, integrating cognitive and functional assessments into bipolar TMS trials would help determine whether mood improvements co-occur with gains in executive control, attention, and processing speed, domains critical for functional recovery. Beyond their role as secondary outcomes, cognitive variables may also shape treatment response itself. Cognitive dysfunction, particularly deficits in executive control, attention, and processing speed, represents a major determinant of functional recovery in bipolar depression (7). However, these deficits may also modulate the brain’s responsiveness to neuromodulation. Impaired cognitive control could signal underlying network rigidity that limits neuroplastic adaptation, whereas preserved executive function may facilitate the reorganization of frontolimbic circuits.

Evidence supporting the interaction between cognitive functioning and treatment response is emerging. Gregory et al. (8) showed that in treatment-resistant unipolar depression, patients with baseline cognitive deficits displayed the greatest post-TMS improvements in verbal memory and executive control, suggesting that cognitive vulnerability may index a plasticity reserve predictive of clinical response. Similarly, Strelnik et al. (9) observed potential cognitive enhancement following TMS in bipolar depression, particularly in verbal and executive domains, although the evidence remains preliminary. In this light, cognition should not be treated merely as a collateral dimension but rather as a mediator and predictor of antidepressant response. Incorporating neuropsychological and neuroimaging measures into future bipolar TMS studies could clarify these links and help develop personalized treatment frameworks targeting both mood and cognitive control.

Building on this, future research should integrate neurophysiological biomarkers, such as electroencephalography-based indices, measures of cortical excitability, and connectivity metrics, to better elucidate the mechanisms underlying treatment response and advance precision neuromodulation. Combining clinical characteristics (e.g., illness duration, polarity index) with neurobiological markers (e.g., baseline network activity or excitability measures) may help identify predictors of response and refine patient selection. As Ventura et al. (3) note, few studies have incorporated such biological or neurophysiological correlates, which represents a critical gap for precision medicine approaches. Moreover, longitudinal investigations are needed to determine whether TMS contributes to relapse prevention or mood stabilization during maintenance phases. The development of adjunctive interventions that combine TMS with psychotherapy, pharmacological agents, or digital monitoring may further enhance the durability and functional impact of treatment effects.

Ventura et al. (3) deliver a pivotal synthesis that consolidates two decades of fragmented evidence into a coherent message: TMS is both effective and safe for bipolar depression. Their work invites the field to move past historical caution and integrate neuromodulation more fully into the therapeutic landscape of bipolar disorder. In doing so, it helps reconcile clinical prudence with scientific evidence, showing that careful optimism, rather than avoidance, is now warranted.

However, as this evidence base matures, the challenge ahead lies in translating symptomatic improvement into sustained cognitive and functional recovery, the true measure of therapeutic success. Ultimately, progress may not rest in distinguishing unipolar from bipolar depression but in identifying shared and dissociable network signatures that predict responsiveness to stimulation (10). As the field evolves, bipolar depression should no longer occupy a peripheral place in TMS research but rather serve as a model for understanding how targeted modulation of neural circuits can bridge mood and cognition and mechanism and meaning.